Feedback / Questions
KAYO-1609 - KayoThera
https://www.businesswire.com/news/home/20230918216063/en/KayoThera-Inc.-Nominates-First-in-Class-Oral-Inhibitor-of-the-Retinoid-Pathway-in-Genetically-Defined-Oncology-Indications-as-a-Development-Candidate
Sep 18, 2023
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious